- Home
- USGO vs SERA Comparison
USGO vs SERA Comparison
Compare USGO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.7M | 130.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USGO | SERA |
|---|---|---|
| Price | $9.70 | $3.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | 37.0K | ★ 54.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | N/A | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $7.26 | $1.37 |
| 52 Week High | $14.93 | $9.13 |
Technical Indicators
Market Signals| Indicator | USGO | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 57.92 |
| Support Level | $9.50 | $3.20 |
| Resistance Level | $10.50 | $3.70 |
| Average True Range (ATR) | 0.56 | 0.28 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 26.98 | 76.93 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.